The Experts below are selected from a list of 324 Experts worldwide ranked by ideXlab platform
Jd Thelma Wright - One of the best experts on this subject based on the ideXlab platform.
-
Stellate Ganglion Block for Debilitating Photophobia Secondary to Trigeminal, Postherpetic Neuralgia.
Pain Practice, 2016Co-Authors: Alexander Sinofsky, Tushar Sharma, Jd Thelma WrightAbstract:Objectives The primary objective of this case report was to demonstrate the therapeutic benefit of stellate ganglion block in trigeminal Postherpetic Neuralgia. Methods This was a case report on a single patient who presented with debilitating photophobia secondary to left-sided trigeminal Postherpetic Neuralgia. A left-sided stellate ganglion block was performed on the patient under fluoroscopic guidance. The primary endpoints were VAS pain scores and changes in functional capacity. Results The patient demonstrated significant reduction in her VAS pain score and improved functional capacity for approximately 6 months after the intervention. This case report provides evidence that sympathectomy via a stellate ganglion block can treat photophobia secondary to Postherpetic Neuralgia in the V1 distribution.
-
Stellate Ganglion Block for Debilitating Photophobia Secondary to Trigeminal, Postherpetic Neuralgia.
Pain practice : the official journal of World Institute of Pain, 2016Co-Authors: Alexander Sinofsky, Tushar Sharma, Jd Thelma WrightAbstract:The primary objective of this case report was to demonstrate the therapeutic benefit of stellate ganglion block in trigeminal Postherpetic Neuralgia. This was a case report on a single patient who presented with debilitating photophobia secondary to left-sided trigeminal Postherpetic Neuralgia. A left-sided stellate ganglion block was performed on the patient under fluoroscopic guidance. The primary endpoints were VAS pain scores and changes in functional capacity. The patient demonstrated significant reduction in her VAS pain score and improved functional capacity for approximately 6 months after the intervention. This case report provides evidence that sympathectomy via a stellate ganglion block can treat photophobia secondary to Postherpetic Neuralgia in the V1 distribution. © 2016 World Institute of Pain.
Akitomo Matsuki - One of the best experts on this subject based on the ideXlab platform.
-
intrathecal methylprednisolone for intractable Postherpetic Neuralgia
The New England Journal of Medicine, 2000Co-Authors: Naoki Kotani, Tetsuya Kushikata, Hiroshi Hashimoto, Futoshi Kimura, Masatoshi Muraoka, Misako Yodono, Mizue Asai, Akitomo MatsukiAbstract:Background There is no effective treatment for intractable Postherpetic Neuralgia. Because there is evidence that Postherpetic Neuralgia has an inflammatory component, we assessed treatment with intrathecally administered methylprednisolone to reduce pain in patients with this disorder. Methods We enrolled 277 patients who had had intractable Postherpetic Neuralgia for at least one year, 270 of whom were followed for two years. The patients were randomly assigned to receive intrathecal methylprednisolone and lidocaine (3 ml of 3 percent lidocaine with 60 mg of methylprednisolone acetate, 89 patients), lidocaine alone (3 ml of 3 percent lidocaine, 91 patients), or no treatment (90 patients) once per week for up to four weeks. Each weekly dose was injected into the lumbar intrathecal space. Pain was evaluated before randomization, at the end of the treatment period, and then four weeks, one year, and two years later. Samples of cerebrospinal fluid were obtained for measurement of interleukin-8 before and at...
Julie Cosserat - One of the best experts on this subject based on the ideXlab platform.
-
Intrathecal methylprednisolone for Postherpetic Neuralgia.
The New England journal of medicine, 2001Co-Authors: Paul J. Zetlaoui, Julie CosseratAbstract:Intrathecal Methylprednisolone for Postherpetic Neuralgia Paul Zetlaoui;Julie Cosserat; The New England Journal of Medicine
C Zhu - One of the best experts on this subject based on the ideXlab platform.
-
corticosteroids for preventing Postherpetic Neuralgia
Cochrane Database of Systematic Reviews, 2013Co-Authors: D Zhang, M Zhou, C ZhuAbstract:Background Postherpetic Neuralgia is a common, serious painful complication of herpes zoster. Corticosteroids are anti-inflammatory and might be beneficial. This is an update of a review first published in 2008 and previously updated in 2010. Objectives To examine the efficacy of corticosteroids in preventing Postherpetic Neuralgia. Search methods We updated the searches for randomised controlled trials (RCTs) of corticosteroids for preventing Postherpetic Neuralgia in the Cochrane Neuromuscular Disease Group Specialized Register (16 April 2012), CENTRAL (2012, Issue 3), MEDLINE (January 1966 to April 2012), EMBASE (January 1980 to April 2012), LILACS (January 1982 to April 2012), and the Chinese Biomedical Retrieval System (1978 to 2012). We also reviewed the bibliographies of identified trials, contacted authors and approached pharmaceutical companies to identify additional published or unpublished data. Selection criteria We included all RCTs involving corticosteroids given by oral, intramuscular, or intravenous routes for people of all ages with herpes zoster of all degrees of severity within seven days after onset, compared with no treatment or placebo but not with other treatments. We did not include quasi-RCTs (trials in which a systematic method of randomisation such as alternation or hospital number was used). Data collection and analysis Two authors identified potential articles, extracted data, and independently assessed the risk of bias of each trial. Disagreement was resolved by discussion among the co-authors. Main results Five trials were included with 787 participants in total. All were randomised, double-blind, placebo-controlled parallel-group studies. We conducted a meta-analysis of two trials (114 participants) and the results gave moderate quality evidence that oral corticosteroids did not prevent Postherpetic Neuralgia six months after the onset of herpes (RR 0.95, 95% CI 0.45 to 1.99). One of these trials was at high risk of bias because of incomplete outcome data, the other was at low risk of bias overall. The three other trials that fulfilled our inclusion criteria were not included in the meta-analysis because the outcomes were reported at less than one month or not in sufficient detail to add to the meta-analysis. These three trials were generally at low risk of bias. Adverse events during or within two weeks after stopping treatment were reported in all five included trials. There were no significant differences in serious or non-serious adverse events between the corticosteroid and placebo groups. There was also no significant difference between the treatment groups and placebo groups in other secondary outcome analyses and subgroup analyses. The review was first published in 2008 and no new RCTs were identified for inclusion in subsequent updates in 2010 and 2012. Authors' conclusions There is moderate quality evidence that corticosteroids given acutely during zoster infection are ineffective in preventing Postherpetic Neuralgia. In people with acute herpes zoster the risks of administration of corticosteroids do not appear to be greater than with placebo, based on moderate quality evidence. Corticosteroids have been recommended to relieve the zoster-associated pain in the acute phase of disease. If further research is designed to evaluate the efficacy of corticosteroids for herpes zoster, long-term follow-up should be included to observe their effect on the transition from acute pain to Postherpetic Neuralgia. Future trials should include measurements of function and quality of life.
-
Corticosteroids for preventing Postherpetic Neuralgia.
The Cochrane database of systematic reviews, 2013Co-Authors: Ying Han, M Zhou, Jingjing Zhang, Ning Chen, C ZhuAbstract:Postherpetic Neuralgia is a common, serious painful complication of herpes zoster. Corticosteroids are anti-inflammatory and might be beneficial. This is an update of a review first published in 2008 and previously updated in 2010. To examine the efficacy of corticosteroids in preventing Postherpetic Neuralgia. We updated the searches for randomised controlled trials (RCTs) of corticosteroids for preventing Postherpetic Neuralgia in the Cochrane Neuromuscular Disease Group Specialized Register (16 April 2012), CENTRAL (2012, Issue 3), MEDLINE (January 1966 to April 2012), EMBASE (January 1980 to April 2012), LILACS (January 1982 to April 2012), and the Chinese Biomedical Retrieval System (1978 to 2012). We also reviewed the bibliographies of identified trials, contacted authors and approached pharmaceutical companies to identify additional published or unpublished data. We included all RCTs involving corticosteroids given by oral, intramuscular, or intravenous routes for people of all ages with herpes zoster of all degrees of severity within seven days after onset, compared with no treatment or placebo but not with other treatments. We did not include quasi-RCTs (trials in which a systematic method of randomisation such as alternation or hospital number was used). Two authors identified potential articles, extracted data, and independently assessed the risk of bias of each trial. Disagreement was resolved by discussion among the co-authors. Five trials were included with 787 participants in total. All were randomised, double-blind, placebo-controlled parallel-group studies. We conducted a meta-analysis of two trials (114 participants) and the results gave moderate quality evidence that oral corticosteroids did not prevent Postherpetic Neuralgia six months after the onset of herpes (RR 0.95, 95% CI 0.45 to 1.99). One of these trials was at high risk of bias because of incomplete outcome data, the other was at low risk of bias overall. The three other trials that fulfilled our inclusion criteria were not included in the meta-analysis because the outcomes were reported at less than one month or not in sufficient detail to add to the meta-analysis. These three trials were generally at low risk of bias. Adverse events during or within two weeks after stopping treatment were reported in all five included trials. There were no significant differences in serious or non-serious adverse events between the corticosteroid and placebo groups. There was also no significant difference between the treatment groups and placebo groups in other secondary outcome analyses and subgroup analyses. The review was first published in 2008 and no new RCTs were identified for inclusion in subsequent updates in 2010 and 2012. There is moderate quality evidence that corticosteroids given acutely during zoster infection are ineffective in preventing Postherpetic Neuralgia. In people with acute herpes zoster the risks of administration of corticosteroids do not appear to be greater than with placebo, based on moderate quality evidence. Corticosteroids have been recommended to relieve the zoster-associated pain in the acute phase of disease. If further research is designed to evaluate the efficacy of corticosteroids for herpes zoster, long-term follow-up should be included to observe their effect on the transition from acute pain to Postherpetic Neuralgia. Future trials should include measurements of function and quality of life.
-
Corticosteroids for preventing Postherpetic Neuralgia.
The Cochrane database of systematic reviews, 2008Co-Authors: D Zhang, M Zhou, C ZhuAbstract:Postherpetic Neuralgia is a common serious complication of herpes zoster. Corticosteroids are anti-inflammatory and might be beneficial. To examine the efficacy of corticosteroids in preventing Postherpetic Neuralgia. Search for randomised or quasi-randomised controlled trials for corticosteroids for preventing Postherpetic Neuralgia in MEDLINE (1950 to 2006), EMBASE (1980 to 2006), LILACS (1982 to 2005), the Chinese Biomedical Retrieval System (1978 to 2006) and the Cochrane Register of Controlled Trials (CENTRAL) (Cochrane Library Issue 3, 2006). Date of most recent search: September 2006. Types of studies: quasi-randomised or randomised controlled trials. people of all ages with herpes zoster of all degrees of severity within seven days after onset. Types of interventions: all kinds of corticosteroids given by oral, intramuscular or intravenous routes during the acute stage (starting within one week of onset of the rash) compared with no treatment or placebo, but not with other treatments. We also included trials which compared corticosteroids plus routine treatment with placebo plus routine treatment. Types of outcome measures: Primary: the presence of Postherpetic Neuralgia six months after the onset of the acute herpetic rash. Secondary: pain severity measured by a validated visual analogue scale or numerical descriptive scale after three, six and 12 months; quality of life measured with the short form 36 questionnaire after six months; adverse events during or within two weeks after stopping treatment. Data were extracted by two independent reviewers. Five trials were included with altogether 787 participants. All were randomised, double-blind, placebo-controlled parallel group studies. Our primary outcome measure was the presence of Postherpetic Neuralgia six months after the onset of the acute herpetic rash. There was no significant difference between the corticosteroid and control groups for the primary outcome (RR 1.27, 95% CI 0.20 to 7.97). There was also no significant difference between the corticosteroid plus antiviral agents and placebo plus antiviral agents groups for the primary outcome (RR 0.90, 95% CI 0.40 to 2.03). No included trials evaluated pain severity with a validated visual analogue scale or numerical descriptive scale and also no trials measured quality of life with the Short Form 36 questionnaire. Adverse events during or within two weeks after stopping treatment were reported by all five included trials, but after meta-analysis, there was no significant difference in any serious adverse event (death, acute cardiac insufficiency, rash dissemination, bacterial pneumonia or haematemesis) or non serious adverse event (dizziness, nausea, vomiting, hypertension or hyperglycaemia). There was insufficient evidence to conclude that corticosteroids are safe or effective in the prevention of Postherpetic Neuralgia. More randomised controlled trials with a greater number of participants are needed to determine reliably whether there is real benefit (or harm) from the use of corticosteroid therapy to prevent Postherpetic Neuralgia. Future trials should measure function and quality of life.
Alexander Sinofsky - One of the best experts on this subject based on the ideXlab platform.
-
Stellate Ganglion Block for Debilitating Photophobia Secondary to Trigeminal, Postherpetic Neuralgia.
Pain Practice, 2016Co-Authors: Alexander Sinofsky, Tushar Sharma, Jd Thelma WrightAbstract:Objectives The primary objective of this case report was to demonstrate the therapeutic benefit of stellate ganglion block in trigeminal Postherpetic Neuralgia. Methods This was a case report on a single patient who presented with debilitating photophobia secondary to left-sided trigeminal Postherpetic Neuralgia. A left-sided stellate ganglion block was performed on the patient under fluoroscopic guidance. The primary endpoints were VAS pain scores and changes in functional capacity. Results The patient demonstrated significant reduction in her VAS pain score and improved functional capacity for approximately 6 months after the intervention. This case report provides evidence that sympathectomy via a stellate ganglion block can treat photophobia secondary to Postherpetic Neuralgia in the V1 distribution.
-
Stellate Ganglion Block for Debilitating Photophobia Secondary to Trigeminal, Postherpetic Neuralgia.
Pain practice : the official journal of World Institute of Pain, 2016Co-Authors: Alexander Sinofsky, Tushar Sharma, Jd Thelma WrightAbstract:The primary objective of this case report was to demonstrate the therapeutic benefit of stellate ganglion block in trigeminal Postherpetic Neuralgia. This was a case report on a single patient who presented with debilitating photophobia secondary to left-sided trigeminal Postherpetic Neuralgia. A left-sided stellate ganglion block was performed on the patient under fluoroscopic guidance. The primary endpoints were VAS pain scores and changes in functional capacity. The patient demonstrated significant reduction in her VAS pain score and improved functional capacity for approximately 6 months after the intervention. This case report provides evidence that sympathectomy via a stellate ganglion block can treat photophobia secondary to Postherpetic Neuralgia in the V1 distribution. © 2016 World Institute of Pain.
